Inozyme Net Debt from 2010 to 2025

INZY Stock

USD 0.97 0.02 2.11%

Inozyme Pharma Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -5.9 M in 2025. Net Debt is the total debt of Inozyme Pharma minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2019-12-31

Previous Quarter

22.2 M

Current Value

25.8 M

Quarterly Volatility

28.2 M

Covid

Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 8 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.16. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.

Check out the analysis of Inozyme Pharma Correlation against competitors.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Net Debt Growth Pattern

Below is the plot of the Net Debt of Inozyme Pharma over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Inozyme Pharma's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Inozyme Net Debt Regression Statistics

	Arithmetic Mean	(34,975,081)
	Coefficient Of Variation	(103.14)
	Mean Deviation	16,569,023
	Median	(35,966,000)
	Standard Deviation	36,072,250
	Sample Variance	1301.2T
	Range	170.6M
	R-Value	0.19
	Mean Square Error	1344.5T
	R-Squared	0.04
	Significance	0.48
	Slope	1,429,848
	Total Sum of Squares	19518.1T

Inozyme Net Debt History

	2025	-5.9 M
	2024	-5.7 M
	2023	12 M
	2022	-26.1 M
	2021	-19.9 M
	2020	-158.6 M
	2019	-31.6 M

Other Fundumenentals of Inozyme Pharma

Net Debt To E B I T D A

Inozyme Pharma Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Long Term Debt	Long Term Debt Total	Short Long Term Debt
Total Assets		0.97	0.94	-0.04	-0.78	0.75	0.73	1.0	0.91	-0.56	0.81	0.99	1.0	0.99	0.78	0.81	0.75	0.37	0.67	-0.31	-0.31
Total Stockholder Equity	0.97		0.95	-0.17	-0.69	0.83	0.58	0.96	0.87	-0.74	0.76	0.98	0.96	0.96	0.66	0.86	0.71	0.28	0.5	-0.24	-0.24
Net Tangible Assets	0.94	0.95		-0.14	-0.77	0.9	0.66	0.95	0.92	-0.66	0.84	0.97	0.93	0.89	0.78	0.88	0.78	0.44	0.53	-0.32	-0.32
Net Debt	-0.04	-0.17	-0.14		-0.39	-0.33	0.32	0.0	0.16	0.43	0.04	-0.05	0.02	-0.03	0.38	-0.03	0.48	0.34	0.49	-0.3	-0.3
Retained Earnings	-0.78	-0.69	-0.77	-0.39		-0.64	-0.94	-0.8	-0.95	0.25	-0.77	-0.78	-0.8	-0.73	-0.92	-0.67	-0.86	-0.83	-0.84	0.74	0.74
Accounts Payable	0.75	0.83	0.9	-0.33	-0.64		0.5	0.75	0.82	-0.78	0.76	0.79	0.72	0.67	0.55	0.85	0.62	0.48	0.22	-0.38	-0.38
Net Receivables	0.73	0.58	0.66	0.32	-0.94	0.5		0.74	0.84	-0.06	0.69	0.7	0.75	0.69	0.87	0.51	0.68	0.83	0.92	-0.78	-0.78
Short Term Investments	1.0	0.96	0.95	0.0	-0.8	0.75	0.74		0.92	-0.54	0.84	0.99	1.0	0.98	0.81	0.83	0.78	0.4	0.69	-0.33	-0.33
Capital Surpluse	0.91	0.87	0.92	0.16	-0.95	0.82	0.84	0.92		-0.53	0.84	0.92	0.91	0.86	0.86	0.83	0.87	0.68	0.7	-0.6	-0.6
Total Liab	-0.56	-0.74	-0.66	0.43	0.25	-0.78	-0.06	-0.54	-0.53		-0.35	-0.62	-0.52	-0.55	-0.11	-0.73	-0.34	-0.06	0.12	0.09	0.09
Deferred Long Term Liab	0.81	0.76	0.84	0.04	-0.77	0.76	0.69	0.84	0.84	-0.35		0.79	0.81	0.75	0.76	0.79	0.78	0.48	0.53	-0.34	-0.34
Net Invested Capital	0.99	0.98	0.97	-0.05	-0.78	0.79	0.7	0.99	0.92	-0.62	0.79		0.99	0.98	0.78	0.84	0.77	0.38	0.63	-0.3	-0.3
Total Current Assets	1.0	0.96	0.93	0.02	-0.8	0.72	0.75	1.0	0.91	-0.52	0.81	0.99		0.99	0.81	0.79	0.77	0.38	0.71	-0.32	-0.32
Net Working Capital	0.99	0.96	0.89	-0.03	-0.73	0.67	0.69	0.98	0.86	-0.55	0.75	0.98	0.99		0.73	0.77	0.71	0.29	0.67	-0.26	-0.26
Common Stock	0.78	0.66	0.78	0.38	-0.92	0.55	0.87	0.81	0.86	-0.11	0.76	0.78	0.81	0.73		0.57	0.87	0.64	0.86	-0.47	-0.47
Property Plant Equipment	0.81	0.86	0.88	-0.03	-0.67	0.85	0.51	0.83	0.83	-0.73	0.79	0.84	0.79	0.77	0.57		0.78	0.39	0.38	-0.3	-0.3
Current Deferred Revenue	0.75	0.71	0.78	0.48	-0.86	0.62	0.68	0.78	0.87	-0.34	0.78	0.77	0.77	0.71	0.87	0.78		0.53	0.65	-0.37	-0.37
Short Term Debt	0.37	0.28	0.44	0.34	-0.83	0.48	0.83	0.4	0.68	-0.06	0.48	0.38	0.38	0.29	0.64	0.39	0.53		0.63	-0.95	-0.95
Long Term Debt	0.67	0.5	0.53	0.49	-0.84	0.22	0.92	0.69	0.7	0.12	0.53	0.63	0.71	0.67	0.86	0.38	0.65	0.63		-0.57	-0.57
Long Term Debt Total	-0.31	-0.24	-0.32	-0.3	0.74	-0.38	-0.78	-0.33	-0.6	0.09	-0.34	-0.3	-0.32	-0.26	-0.47	-0.3	-0.37	-0.95	-0.57		1.0
Short Long Term Debt	-0.31	-0.24	-0.32	-0.3	0.74	-0.38	-0.78	-0.33	-0.6	0.09	-0.34	-0.3	-0.32	-0.26	-0.47	-0.3	-0.37	-0.95	-0.57	1.0

Click cells to compare fundamentals

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-5.7 M	-5.9 M
Net Debt To EBITDA	0.05	0.05

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inozyme Net Debt from 2010 to 2025

Latest Inozyme Pharma's Net Debt Growth Pattern

Inozyme Net Debt Regression Statistics

Inozyme Net Debt History

Other Fundumenentals of Inozyme Pharma

Inozyme Pharma Net Debt component correlations

About Inozyme Pharma Financial Statements

Also Currently Popular

Additional Tools for Inozyme Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY